Fidelity Advisor Biotechnology Fund - Class C FBTCX

Morningstar Medalist Rating
  • NAV / 1-Day Return$35.44  /  −1.31%
  • Fund Size$2.4B
  • Adjusted Expense Ratio1.690%
  • Net Expense Ratio1.690%
  • Fee Level: DistributionLow
  • Share Class TypeLevel Load
  • Morningstar CategoryHealth
  • Equity Style Box (Funds)Mid Blend
  • Minimum Initial Investment$0
  • Investment StatusOpen
  • TTM Yield1.05%
  • Turnover Ratio54%

Morningstar’s Analysis FBTCX

Will FBTCX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Fidelity Advisor Biotechnology C holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FBTCX

  • Current Portfolio Date
  • Equity Holdings—
  • Bond Holdings—
  • Other Holdings—
  • % Assets in Top 10 Holdings50.7
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

AbbVie Inc

17.52412M
Healthcare

Gilead Sciences Inc

5.29124M
Healthcare

Moderna Inc

4.43104M
Healthcare

Alnylam Pharmaceuticals Inc

3.9693M
Healthcare

Natera Inc

3.7688M
Healthcare

Insmed Inc

3.3078M
Healthcare

Spyre Therapeutics Inc

3.2576M
Healthcare

argenx SE ADR

3.1574M
Healthcare

Revolution Medicines Inc Ordinary Shares

3.0872M
Healthcare

Amylyx Pharmaceuticals Inc

3.0171M
Healthcare

Sponsor Center